Swing Trade Stock Picks

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/24/2017 – 07/28/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.62
b. Sell at >~ $5.80

2) CYCC – Cyclacel Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.72
b. Sell at >~ $3.00
c. Catalysts:
1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
3. Phase 2 – Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation; 20170801; 20171031; https://ClinicalTrials.gov/show/NCT02649751
4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460
6. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

3) UNXL – Uni-Pixel Inc
a. Buy at < ~ $0.35
b. Sell at >~ $0.60

4) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.32
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

5) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

6) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.47
b. Sell at >~ $2.05
c. Catalysts:
1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

8) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
a. Buy at < ~ $4.60
b. Sell at >~ $6.05
c. Catalysts:
1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/24/2017 – 07/28/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 07/21/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
7. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.82
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $3.19
9. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 07/21/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
5. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.81
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 07/31/2017 – 08/04/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $5.80

2) CYCC – Cyclacel Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.71
b. Sell at >~ $3.00
c. Catalysts:
1. Phase 1 – A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://ClinicalTrials.gov/show/NCT00999401
2. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
3. Phase 2 – Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation; 20170801; 20171031; https://ClinicalTrials.gov/show/NCT02649751
4. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
5. Phase 2 – Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23); 20190701; 20190731; https://ClinicalTrials.gov/show/NCT01253460
6. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

3) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.32
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

4) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. Phase 2b enrollment due to be completed in a few weeks (noted July 12, 2017) with interim efficacy analysis due 6 months following – i.e. likely 1Q 2018. – NeuVax in combination with Herceptin – Breast cancer – Phase 2b; 20180331; 20180331; https://investors.galenabiopharma.com/investors/press-releases/press-release-details/2017/Galena-Biopharma-Provides-Corporate-Update/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1
5. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
6. Phase 2 – Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT02297698
7. Phase 2 – Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax; 20190601; 20200630; https://ClinicalTrials.gov/show/NCT01570036

5) ANTH – Anthera Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $1.38
b. Sell at >~ $2.05
c. Catalysts:
1. Phase 4 – EASY: Extended Access to Sollpura Over Years; 20170901; 20171231; https://ClinicalTrials.gov/show/NCT02823964
2. Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017. – Blisibimod – IgA nephropathy – Phase 2; 20170630; 20170930; http://investor.anthera.com/releasedetail.cfm?ReleaseID=1025900
3. Phase 3 – BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy; 20161001; 20211031; https://ClinicalTrials.gov/show/NCT02052219
4. Phase 3 – CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis; 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02074020
5. Phase 3 data due end of 2017 or early 2018. – Sollpura – RESULT – Exocrine pancreatic insufficiency – Phase 3; 20180331; 20180331; http://files.shareholder.com/downloads/ABEA-3R5RJ7/2039745217x0x948640/5EE14DFC-C765-43AD-B65D-BC5471C38EB7/ANTH_News_2017_7_6_General_Releases.pdf
6. Phase 3 – RESULT: Reliable, Emergent Solution Using Liprotamase Treatment; 20171101; 20171231; https://ClinicalTrials.gov/show/NCT03051490

6) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.11
b. Sell at >~ $2.45

7) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
a. Buy at < ~ $4.60
b. Sell at >~ $6.05
c. Catalysts:
1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

8) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $3.26
b. Sell at >~ $4.00

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 07/31/2017 – 08/04/2017, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 07/28/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
7. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $3.19
8. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 07/28/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
4. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
5. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.81
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/07/2017 – 08/11/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $5.80

2) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.40
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

3) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. Phase 2b enrollment due to be completed in a few weeks (noted July 12, 2017) with interim efficacy analysis due 6 months following – i.e. likely 1Q 2018. – NeuVax in combination with Herceptin – Breast cancer – Phase 2b; 20180331; 20180331; https://investors.galenabiopharma.com/investors/press-releases/press-release-details/2017/Galena-Biopharma-Provides-Corporate-Update/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Q2 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170807; 20170807; https://www.google.com/finance?q=GALE
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1
5. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
6. Phase 2 – Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients; 20191201; 20201231; https://ClinicalTrials.gov/show/NCT02297698
7. Phase 2 – Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax; 20190601; 20200630; https://ClinicalTrials.gov/show/NCT01570036

4) AGTC – Applied Genetic Technologies Corp – Trading Below Cash
a. Buy at < ~ $4.50
b. Sell at >~ $6.05
c. Catalysts:
1. Phase 1Phase 2 – Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS); 20171201; 20201231; https://ClinicalTrials.gov/show/NCT02416622
2. Phase 1Phase 2 – Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis; 20140901; 20271231; https://ClinicalTrials.gov/show/NCT00749957
3. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia; 20190601; 20230630; https://ClinicalTrials.gov/show/NCT02935517
4. Phase 1Phase 2 – Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia; 20181201; 20221231; https://ClinicalTrials.gov/show/NCT02599922

5) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $3.11
b. Sell at >~ $4.00

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/07/2017 – 08/11/2017, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 08/04/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $ANTH – Anthera Pharmaceuticals Inc :
   1. Cash/sh = $1.97
3. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.97
4. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Cash/sh = $1.93
5. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
6. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
7. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.91
8. $EGLT – Egalet Corp :
   1. Cash/sh = $2.30
9. $OPHT – Ophthotech Corp :
   1. Cash/sh = $6.30
10. $ROKA – Roka Bioscience Inc :
    1. Cash/sh = $3.19
11. $TNDM – Tandem Diabetes Care Inc :
    1. Cash/sh = $0.92

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 08/04/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Book/sh = $3.00
4. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
5. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.99
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/14/2017 – 08/18/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $5.80

2) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.36
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

3) ONCS – OncoSec Medical Inc
a. Buy at < ~ $0.88
b. Sell at >~ $1.30
c. Catalysts:
1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
2. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

4) AGLE – Aeglea Bio Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.81
b. Sell at >~ $4.00

5) SCYX – SCYNEXIS Inc – Trading Below Cash
a. Buy at < ~ $1.52
b. Sell at >~ $2.00
c. Catalysts:
1. Mid-2017 – Submission of IV data analysis to FDA; 20170601; 20171231; https://twitter.com/crewdog58/status/871138614591270912
2. Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases (FURI); 20190901; 20191231; https://clinicaltrials.gov/ct2/show/NCT03059992?term=SCYNEXIS&rank=3

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/14/2017 – 08/18/2017, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 08/18/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $ANTH – Anthera Pharmaceuticals Inc :
   1. Cash/sh = $1.97
3. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.95
4. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Cash/sh = $1.93
5. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $2.36
6. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
7. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.85
8. $EGLT – Egalet Corp :
   1. Cash/sh = $2.30
9. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.44
10. $ROKA – Roka Bioscience Inc :
    1. Cash/sh = $3.19
11. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Cash/sh = $3.04

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 08/18/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.63
3. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Book/sh = $3.00
4. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $1.90
5. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.73
6. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
7. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.19
8. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $22.22
9. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
10. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Book/sh = $5.51

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 08/28/2017 – 09/01/2017:

1) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.36
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

2) ONCS – OncoSec Medical Inc
a. Buy at < ~ $0.88
b. Sell at >~ $1.30
c. Catalysts:
1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
2. Q4 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20171011; 20171011; https://www.google.com/finance?q=ONCS
3. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

3) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.10
b. Sell at >~ $1.38

4) TRIL – Trillium Therapeutics Inc.
a. Buy at < ~ $4.15
b. Sell at >~ $4.95
c. Catalysts:
1. Phase 2 – Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer; 20170930; 20170930; https://ClinicalTrials.gov/show/NCT01010126
2. NA – A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting; 20170815; 20181030; https://ClinicalTrials.gov/show/NCT02364531
3. Phase 3 – Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT00324805
4. Phase 3 – Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial); 20171231; 20171231; https://ClinicalTrials.gov/show/NCT00310180
5. Phase 1Phase 2 – Thoracic Surgery Extended Low-Molecular Weight Heparin VTE Prophylaxis–Pilot Trial; 20170601; 20170831; https://ClinicalTrials.gov/show/NCT02334007
6. Phase 3 – Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer; 20140601; 20200630; https://ClinicalTrials.gov/show/NCT00066703
7. Phase 3 – A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer; 20110513; 20220312; https://ClinicalTrials.gov/show/NCT00567190
8. Phase 4 – Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes; 20170501; 20171031; https://ClinicalTrials.gov/show/NCT01351857
9. Phase 3 – Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer; 20150201; 20171231; https://ClinicalTrials.gov/show/NCT00265850
10. Phase 3 – Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer; 20180501; 20180531; https://ClinicalTrials.gov/show/NCT00463489
11. Phase 3 – A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer; 20200101; 20200731; https://ClinicalTrials.gov/show/NCT01101438
12. NA – Womens Initiative Supporting Health Increasing Healthcare Access; 20190601; 20190731; https://ClinicalTrials.gov/show/NCT02964845
13. Phase 3 – Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer; 20220201; 20220228; https://ClinicalTrials.gov/show/NCT01272037
14. Phase 3 – High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery; 20200601; 20200601; https://ClinicalTrials.gov/show/NCT02506153
15. Phase 1 – A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02663518
16. Phase 1 – Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides; 20181201; 20191231; https://ClinicalTrials.gov/show/NCT02890368
17. Phase 3 – Effect of MD1003 in Progressive Multiple Sclerosis (SPI2); 20180901; 20190930; https://ClinicalTrials.gov/show/NCT02936037
18. Phase 3 – Field Randomization of NA-1 Therapy in Early Responders; 20190301; 20190531; https://ClinicalTrials.gov/show/NCT02315443
19. Phase 3 – FIBrinogen REplenishment in Surgery; 20190130; 20190330; https://ClinicalTrials.gov/show/NCT03037424

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 08/28/2017 – 09/01/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 09/05/2017 – 09/08/2017:

1) OTIC – Otonomy Inc – Trading Below Cash
a. Buy at < ~ $3.30
b. Sell at >~ $10.50
c. Catalysts:
1. Phase 3 – Study of OTO-104 in Subjects With Unilateral Menieres Disease; 20171101; 20171130; https://ClinicalTrials.gov/show/NCT02717442
2. Q3 2017 Otonomy Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=OTIC
3. Phase 2 – Open Label Study of OTO-104 in Subjects With Menieres Disease; 20171001; 20171031; https://ClinicalTrials.gov/show/NCT02740387
4. Phase 3 trial met primary endpoint – January 5, 2017. PDUFA date for sNDA filing March 2, 2018. – OTIPRIO – Acute otitis externa – Phase 3; 20180302; 20180302; http://investors.otonomy.com/phoenix.zhtml?c=234082&p=irol-newsArticle_Print&ID=2286970
5. Phase 2 – Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss; 20180301; 20180630; https://ClinicalTrials.gov/show/NCT02997189
6. Phase 3 – A 6-Month Extension Study of OTO-104 in Menieres Disease; 20180101; 20180131; https://ClinicalTrials.gov/show/NCT02706730

2) HEB – Hemispherx BioPharma, Inc
a. Buy at < ~ $0.36
b. Sell at >~ $0.75
c. Catalysts:
1. Phase 1Phase 2 – Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines; 20170701; 20201231; https://ClinicalTrials.gov/show/NCT02432378
2. Phase 1Phase 2 – Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer; 20171201; 20181231; https://ClinicalTrials.gov/show/NCT01545141
3. Phase 3 – Ampligen in Chronic Fatigue Syndrome; 20190201; 20190228; https://ClinicalTrials.gov/show/NCT00215813

3) ONCS – OncoSec Medical Inc
a. Buy at < ~ $0.88
b. Sell at >~ $1.30
c. Catalysts:
1. Phase 2 enrollment to commence June 2017 with data due 4Q 2017. – ImmunoPulse IL-12 – Melanoma – cancer – Phase 2; 20171001; 20171231; http://ir.oncosec.com/press-releases/detail/1907
2. Q4 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20171011; 20171011; https://www.google.com/finance?q=ONCS
3. Phase 2Phase 3 – pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment; 20180901; 20191201; https://ClinicalTrials.gov/show/NCT03132675

4) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.10
b. Sell at >~ $1.38

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 09/05/2017 – 09/08/2017, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 09/01/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $0.95
3. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Cash/sh = $1.93
4. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
5. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.85
6. $EGLT – Egalet Corp :
   1. Cash/sh = $2.30
7. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.44
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $1.68

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 09/01/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Book/sh = $1.71
2. $CYCC – Cyclacel Pharmaceuticals Inc :
   1. Book/sh = $3.00
3. $ECYT – Endocyte, Inc. :
   1. Book/sh = $2.73
4. $LBIX – Leading Brands, Inc (USA) :
   1. Book/sh = $1.19
5. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $22.22
6. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $2.44

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 10/01/2017 include:

1. $ADHD – Alcobra Ltd :
   1. Cash/sh = $1.81
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.00
3. $EARS – Auris Medical Holding AG :
   1. Cash/sh = $1.12
4. $ECYT – Endocyte, Inc. :
   1. Cash/sh = $2.80
5. $LBIX – Leading Brands, Inc (USA) :
   1. Cash/sh = $0.98
6. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.44
7. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.69
8. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $1.68
9. $RTTR – Ritter Pharmaceuticals Inc :
   1. Cash/sh = $0.42
10. $TNXP – Tonix Pharmaceuticals Holding Corp. :
    1. Cash/sh = $4.67

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/09/2017 – 10/13/2017:

1) ROSG – Rosetta Genomics Ltd. (USA)
a. Buy at < ~ $0.98
b. Sell at >~ $1.40
c. Catalysts:
1. The sale of PDx is expected to close within the next several weeks; 20170908; 20171231; https://finance.yahoo.com/news/rosetta-genomics-enters-agreement-sell-123000567.html

2) ARTW – Arts-Way Manufacturing Co. Inc.
a. Buy at < ~ $2.40
b. Sell at >~ $3.50

3) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.50
b. Sell at >~ $1.99
c. Catalysts:
1. Phase 3 – Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01928537
2. Phase 3 enrolling. Interim analysis due 4Q 2017. Noted August 15, 2017 that enrollment has been slower than expected. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20171231; 20171231; http://investor.onconova.com/releasedetail.cfm?ReleaseID=1037302
3. Phase 2 – Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01904682
4. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm
5. Phase 3 – Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts; 20171201; 20180531; https://ClinicalTrials.gov/show/NCT01241500
6. Phase 1Phase 2 – Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine; 20180601; 20181031; https://ClinicalTrials.gov/show/NCT01926587
7. Phase 2 – Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia; 20220801; 20220831; https://ClinicalTrials.gov/show/NCT02730884
8. Phase 3 – Controlled Study of Rigosertib Versus Physicians Choice of Treatment in MDS Patients After Failure of an HMA; 20180601; 20180930; https://ClinicalTrials.gov/show/NCT02562443
9. Phase 1 – Three Dosing Schedules of Oral Rigosertib in MDS Patients; 20180401; 20181031; https://ClinicalTrials.gov/show/NCT02075034
10. Phase 1 – Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors; 20180501; 20181231; https://ClinicalTrials.gov/show/NCT02168725

4) EVAR – Lombard Medical Inc – Trading Below Cash
a. Buy at < ~ $0.40
b. Sell at >~ $0.50
c. Catalysts:
1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/09/2017 – 10/13/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/16/2017 – 10/20/2017:

1) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.60
b. Sell at >~ $4.99
c. Catalysts:
1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=ONVO

2) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $1.01
b. Sell at >~ $1.59
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

3) VVUS – VIVUS, Inc. – Trading Below Cash
a. Buy at < ~ $0.86
b. Sell at >~ $1.30
c. Catalysts:
1. Q3 2017 VIVUS Inc Earnings Release (Estimated)
-; 20171107; 20171107; https://www.google.com/finance?q=VVUS
2. Phase 2 – Qsymia as an Adjunct to Surgical Therapy in the Superobese; 20171201; 20171231; https://ClinicalTrials.gov/show/NCT02301416

4) ROSG – Rosetta Genomics Ltd. (USA)
a. Buy at < ~ $0.98
b. Sell at >~ $1.40
c. Catalysts:
1. The sale of PDx is expected to close within the next several weeks; 20170908; 20171231; https://finance.yahoo.com/news/rosetta-genomics-enters-agreement-sell-123000567.html

5) ARTW – Arts-Way Manufacturing Co. Inc.
a. Buy at < ~ $2.40
b. Sell at >~ $3.50

6) EVAR – Lombard Medical Inc – Trading Below Cash
a. Buy at < ~ $0.40
b. Sell at >~ $0.50
c. Catalysts:
1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/16/2017 – 10/20/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/23/2017 – 10/27/2017:

1) ARTW – Arts-Way Manufacturing Co. Inc.
a. Buy at < ~ $2.40
b. Sell at >~ $3.50

2) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80
c. Catalysts:
1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=ONVO

3) EVAR – Lombard Medical Inc
a. Buy at < ~ $0.40
b. Sell at >~ $0.50
c. Catalysts:
1. Phase 4 – AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft; 20170401; 20220430; https://ClinicalTrials.gov/show/NCT02480595
2. NA – Prospective Aneurysm Trial: High Angle Aorfix™ Bifurcated Stent Graft; 20110901; 20180131; https://ClinicalTrials.gov/show/NCT00522535
3. NA – Treating Cognitive Deficits in Spinal Cord Injury; 20200131; 20200131; https://ClinicalTrials.gov/show/NCT03037879
4. NA – Aorfix Intelliflex First in Human Study; 20171101; 20211130; https://ClinicalTrials.gov/show/NCT02907762

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/23/2017 – 10/27/2017, and Why?

[Michael DeVries]

Bullish Stocks currently Trading Below Cash (TBC) as of 10/20/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.00
2. $EGLT – Egalet Corp :
   1. Cash/sh = $2.03
3. $OPHT – Ophthotech Corp :
   1. Cash/sh = $5.48
4. $ROKA – Roka Bioscience Inc :
   1. Cash/sh = $2.84
5. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $3.54
6. $VVUS – VIVUS, Inc. :
   1. Cash/sh = $2.39

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 10/20/2017 include:

1. $HEB – Hemispherx BioPharma, Inc :
   1. Book/sh = $0.51
2. $MICT – Micronet Enertec Technologies Inc :
   1. Book/sh = $0.80
3. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $21.86
4. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
5. $ROSG – Rosetta Genomics Ltd. (USA) :
   1. Book/sh = $2.40

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 10/30/2017 – 11/03/2017:

1) CEMP – Cempra Inc – Trading Below Cash
a. Buy at < ~ $2.05
b. Sell at >~ $3.50
c. Catalysts:
1. Phase 2Phase 3 – Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated; 20171001; 20181231; https://ClinicalTrials.gov/show/NCT02569541
2. Phase 2/3 data due by the end of 2017. – Taksta – Fusidic acid – Refractory infections in bones and joints – Phase 2/3; 20171231; 20171231; http://investor.cempra.com/secfiling.cfm?filingid=1193125-17-252119&CIK=1461993
3. Phase 2Phase 3 – Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bacterial Pneumonia; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02605122

2) EGLT – Egalet Corp – Trading Below Cash
a. Buy at < ~ $0.97
b. Sell at >~ $1.54
c. Catalysts:
1. Phase 3 to be completed 4Q 2017. NDA planned for 2018. – Egalet-002 – Moderate to severe chronic pain – Phase 3; 20171001; 20171231; http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11315453&type=HTML&symbol=EGLT&companyName=Egalet+Corporation&formType=8-K&dateFiled=2017-01-09

3) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80
c. Catalysts:
1. Q2 2018 Organovo Holdings Inc Earnings Release (Estimated)
-; 20171101; 20171101; https://www.google.com/finance?q=ONVO

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 10/30/2017 – 11/03/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook (#TBB ) as of 10/27/2017 include:

1. $EVAR – Lombard Medical Inc :
   1. Book/sh = $0.89
2. $HEB – Hemispherx BioPharma, Inc :
   1. Book/sh = $0.51
3. $MICT – Micronet Enertec Technologies Inc :
   1. Book/sh = $0.80
4. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $21.42
5. $ROKA – Roka Bioscience Inc :
   1. Book/sh = $5.93
6. $ROSG – Rosetta Genomics Ltd. (USA) :
   1. Book/sh = $2.40

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 11/13/2017 – 11/17/2017:

1) PERI – Perion Network Ltd
a. Buy at < ~ $0.94
b. Sell at >~ $2.00

2) GNCA – Genocea Biosciences Inc – Trading Below Cash
a. Buy at < ~ $1.03
b. Sell at >~ $2.00
c. Catalysts:
1. Phase 2 – Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection; 20180630; 20180630; https://ClinicalTrials.gov/show/NCT03146403
2. NA – Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity; 20181201; 20181231; https://ClinicalTrials.gov/show/NCT02910284

3) ABIL – Ability Inc
a. Buy at < ~ $0.57
b. Sell at >~ $1.00

4) VICL – Vical Incorporated – Trading Below Cash
a. Buy at < ~ $1.66
b. Sell at >~ $2.70
c. Catalysts:
1. Initiated Phase 3 Jun 2013. Enrollment due to be completed 3Q 2016. Topline data due 1Q2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180101; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2016/Vical-Reports-Third-Quarter-2016-Financial-Results/default.aspx
2. Phase 3 trial completion announced November 10, 2017. Top-line data due 1Q 2018. – ASP0113 Vaccine – Hematopoietic cell transplant recipients – Phase 3; 20180331; 20180331; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx
3. Phase 2 trial initiated September 2016. Enrollment completion announced April 19, 2017 with data due 2Q 2018. – VCL-HB01 HSV-2 Therapeutic Vaccine – Genital Herpes in Adults – Phase 2; 20180630; 20180630; http://www.vical.com/investors/news-releases/News-Release-Details/2017/Vical-Reports-Third-Quarter-2017-Financial-and-Operational-Results/default.aspx

5) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.10
b. Sell at >~ $1.75

6) XENE – Xenon Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $2.25
b. Sell at >~ $3.00
c. Catalysts:
1. NA – Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility; 20180801; 20180831; https://ClinicalTrials.gov/show/NCT02484885
2. NA – Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair; 20180701; 20180930; https://ClinicalTrials.gov/show/NCT02774096
3. NA – Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis; 20181001; 20181031; https://ClinicalTrials.gov/show/NCT02912637
4. Phase 1Phase 2 – Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy; 20181231; 20191231; https://ClinicalTrials.gov/show/NCT03331302
5. Phase 3 – A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy; 20181201; 20190531; https://ClinicalTrials.gov/show/NCT03054870
6. Early Phase 1 – New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD); 20180601; 20180630; https://ClinicalTrials.gov/show/NCT02826343
7. NA – Xenon Against Postoperative Oxygen Impairment; 20170701; 20171231; https://ClinicalTrials.gov/show/NCT02468531
8. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
9. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
10. Phase 1Phase 2 – Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration; 20180201; 20190228; https://ClinicalTrials.gov/show/NCT02316379
11. Phase 1Phase 2 – Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults; 20171101; 20181130; https://ClinicalTrials.gov/show/NCT02272049
12. Phase 1 – Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis; 20190401; 20190430; https://ClinicalTrials.gov/show/NCT02478268
13. NA – A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease; 20201001; 20201031; https://ClinicalTrials.gov/show/NCT02723474
14. Phase 1 – Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study; 20200901; 20200930; https://ClinicalTrials.gov/show/NCT02220426
15. Phase 1 – Hyperpolarized 129Xe MRI for Imaging Pulmonary Function; 20201201; 20211231; https://ClinicalTrials.gov/show/NCT01280994
16. NA – Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI; 20210801; 20211231; https://ClinicalTrials.gov/show/NCT02848560
17. Phase 2 – Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics; 20201231; 20220131; https://ClinicalTrials.gov/show/NCT03002389
18. NA – 129 Xenon MRI in Chronic Lung Disease; 20200801; 20200831; https://ClinicalTrials.gov/show/NCT02723500
19. Early Phase 1 – HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimers Disease; 20190601; 20190630; https://ClinicalTrials.gov/show/NCT02638519
20. Phase 2 – A Test of Neural Inertia in Humans With Xenon; 20190401; 20190831; https://ClinicalTrials.gov/show/NCT02768727
21. Phase 2 – Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02740868
22. Phase 2 – Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth; 20190831; 20190831; https://ClinicalTrials.gov/show/NCT02071394
23. Phase 1 – Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment; 20190801; 20190831; https://ClinicalTrials.gov/show/NCT02478255

7) PRSS – CafePress Inc
a. Buy at < ~ $1.67
b. Sell at >~ $2.20

8) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $0.80
b. Sell at >~ $1.05
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. Q2 2018 Oasmia Pharmaceutical AB Earnings Release (Estimated); 20171130; 20171130; https://www.google.com/finance?q=OASM

9) ONVO – Organovo Holdings Inc
a. Buy at < ~ $1.38
b. Sell at >~ $1.80

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 11/13/2017 – 11/17/2017, and Why?

[Author]

Posts